New obesity drug LAE103 enters first human safety trials
NCT ID NCT07230496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety and tolerability of a new injectable drug called LAE103 in healthy overweight or obese adults, and in healthy postmenopausal women. Researchers will also test LAE103 combined with another drug, LAE102. The goal is to find out if the drug is safe and how the body processes it, not yet to prove weight loss. About 104 participants will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Q-Pharm Pty Ltd.
RECRUITINGBrisbane, Queensland, 4006, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?